Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Hybrid — also manufactures internal programs
369 confirmed programs
· 118 sponsors
· Last scored 2026-11-12
90.1
Signal Score
✓ FDA Inspections (4)
✓ Clinical Trials (369)
✓ SEC Filings (20)
○ Press
✓ EMA GMP (15)
○ MHRA GMP
Quick Facts: Pfizer CentreOne
- Signal Score
- 90.1/100 (as of 2026-11-12)
- Quality Compliance
- 100.0/100 — Clean EMA record: 14 active GMP certificates (no deductions)
- Headquarters
- Kalamazoo, MI · McPherson, KS
- Modalities
- Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
- Active Programs
- 369 confirmed from ClinicalTrials.gov across 118 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Pfizer CentreOne
Pfizer's contract manufacturing arm.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Clean EMA record: 14 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP
Clean EMA record: 14 active GMP certificates (no deductions)
FDA Inspections4 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-12-16)
EMA GMP Certificates15 on record
Clean EMA record: 14 active GMP certificates (no deductions)
Operations
93.8
369 active programs across 118 sponsors
Modalities: Small Molecule API, Sterile Fill-Finish, Oral Solid Dose, mRNA, High-Potency APIs, Biologics
213 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
369 active programs across 118 sponsors · Modalities: Small Molecule API, Sterile Fill-Finish, Oral Solid Dose, mRNA, High-Potency APIs, Biologics · 213 programs in advanced phases (Phase 2/3)
Programs
369
Sponsors118
ModalitiesBiologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
369 active programs across 118 sponsors
Modalities: Small Molecule API, Sterile Fill-Finish, Oral Solid Dose, mRNA, High-Potency APIs, Biologics
213 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07663630
A Study to Learn About the Study Medicine Called Ponsegromab...
PHASE1
Not Yet Recruiting
NCT07812467
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral...
PHASE2
Not Yet Recruiting
NCT07782359
Impact of Using a GLP1 on Treatment Related Side Effects of...
PHASE1
Not Yet Recruiting
View all 369 programs →
Source: ClinicalTrials.gov · Retrieved Nov 22, 2026
Financial Stability
83.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
20 SEC filings with industry mentions on record (shown, not scored)
SEC Filings20 with industry mentions (not scored)
Publicly traded — financial transparency
Capacity
75.0
Multi-site operations (4 manufacturing sites)
Broad modality coverage (6 modalities)
Sites: Kalamazoo, MI, McPherson, KS, Freiburg, Germany, Newbridge, Ireland
Source: company profiles (manufacturing sites, modality breadth)
4 manufacturing sites
Multi-site operations (4 manufacturing sites)
Broad modality coverage (6 modalities)
Pfizer CentreOne FDA Inspection History
2025-12
2025-10
2025-08
2025-06
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2025-12-16 |
Pfizer Inc
Pleasant Prairie, Wisconsin
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2025-10-24 |
Pfizer, Inc.
Groton, Connecticut
Facility-linked
|
Bioresearch Monitoring | Not posted | Voluntary Action Indicated (VAI) |
| 2025-08-22 |
Pfizer Inc.
San Diego, California
Facility-linked
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
| 2025-06-18 |
Pfizer, Inc.
Parsippany, New Jersey
Facility-linked
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Nov 22, 2026
Pfizer CentreOne EMA GMP Compliance 15 certificates
2026-03
2026-03
2025-11
2025-11
2025-11
2025-08
2025-08
2025-07
2025-04
2024-10
2024-10
2022-09
2022-09
2022-09
2021-07
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| CRN00GZYJ/M11173/00001 | Pfizer Ireland Pharmaceuticals Unlimited CompanyAlternative Name:Pfizer Ireland Pharmaceuticals | Ireland | 2026-03-27 | COMPLIANT |
| CRN00GZYJ/IMP11510/00001 | Pfizer Ireland Pharmaceuticals Unlimited CompanyAlternative Name:Pfizer Ireland Pharmaceuticals | Ireland | 2026-03-27 | COMPLIANT |
| CRN00GTL9-ASR11421/00001 | Pfizer Ireland Pharmaceuticals Unlimited CompanyAlternative Name:Pfizer Ireland Pharmaceuticals | Ireland | 2025-11-21 | COMPLIANT |
| CRN00GTL9-M1063/00001 | Pfizer Ireland Pharmaceuticals Unlimited CompanyAlternative Name:Pfizer Ireland Pharmaceuticals | Ireland | 2025-11-21 | COMPLIANT |
| CRN00GTL9-IMP070/00001 | Pfizer Ireland Pharmaceuticals Unlimited Company | Ireland | 2025-11-21 | COMPLIANT |
| 36270/M11173/00001 | Pfizer Ireland Pharmaceuticals Unlimited CompanyAlternative Name:Pfizer Ireland Pharmaceuticals | Ireland | 2025-08-07 | COMPLIANT |
| 36270/IMP11510/00001 | Pfizer Ireland Pharmaceuticals Unlimited CompanyAlternative Name:Pfizer Ireland Pharmaceuticals | Ireland | 2025-08-07 | COMPLIANT |
| DE_BW_01_GMP_2025_0205 | Pfizer Manufacturing Deutschland GmbH | Germany | 2025-07-02 | COMPLIANT |
| 35854/IMP 13426/00001 | Pfizer Ireland Pharmaceuticals Unlimited Company | Ireland | 2025-04-16 | COMPLIANT |
| 35284/ASR11424/1B | Pfizer Ireland Pharmaceuticals Unlimited Company | Ireland | 2024-10-25 | COMPLIANT |
| 35320/IMP11510-00002 | Pfizer Ireland Pharmaceuticals Unlimited Company | Ireland | 2024-10-08 | COMPLIANT |
| 33578-IMP070/00001 | Pfizer Ireland Pharmaceuticals | Ireland | 2022-09-23 | COMPLIANT |
| CRN00GWFF-M1063/00001 | Pfizer Ireland Pharmaceuticals Unlimited CompanyAlternative Name:Pfizer Ireland Pharmaceuticals | Ireland | 2022-09-23 | COMPLIANT |
| 33578-ASR11421/00001 | Pfizer Ireland Pharmaceuticals | Ireland | 2022-09-23 | COMPLIANT |
| AUR23-20/ASR11424 | Pfizer Ireland Pharmaceuticals | Ireland | 2021-07-16 | NON-COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 22, 2026
Japan-accredited overseas site (PMDA)
general (non-sterile) · 1 site · own products, not contract-manufacturing evidence
- Freiburg Im Breisgau, Germany · Pfizer Manufacturing Deutschland GmbH — general (non-sterile) · valid to Mar 26, 2031
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. These approvals cover the company's own products; they are not evidence of contract manufacturing. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Clinical Activity 369 studies
NCT07663630
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With...
PHASE1
Not Yet Recruiting
NCT07812467
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or...
PHASE2
Not Yet Recruiting
NCT07782359
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer...
PHASE1
Not Yet Recruiting
NCT06507904
A Study to Learn How Different Preparations of Osivelotor Taste and Enter...
PHASE1
Not Yet Recruiting
NCT07476287
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called...
PHASE2
Recruiting
NCT07489066
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in...
PHASE2
Recruiting
NCT07556549
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment...
NA
Active Not Recruiting
NCT07567352
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who...
NA
Active Not Recruiting
NCT07227415
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404...
PHASE1/PHASE2
Recruiting
NCT07222566
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called...
PHASE3
Recruiting
NCT07226999
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called...
PHASE2/PHASE3
Recruiting
NCT07261371
A Study to Compare Blood Levels of Different Dosage Formulations of the...
PHASE1
Completed
NCT07123090
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
PHASE2
Recruiting
NCT06974786
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and...
PHASE2
Recruiting
NCT06758401
This is a Study to Learn About How the Combination of the Study Medicines...
PHASE3
Recruiting
NCT06918002
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus...
PHASE3
Recruiting
NCT06987734
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for...
PHASE2
Recruiting
NCT06634836
Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B
NA
Withdrawn
NCT06218069
Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor
PHASE2/PHASE3
Not Yet Recruiting
NCT06799026
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma...
PHASE1
Recruiting
+ 349 more studies
Source: ClinicalTrials.gov · Retrieved Nov 22, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (94 postings on Nov 21, 2026), and we can't yet tell which of those roles belong to it. Why: the group's board only shows its ~100 newest postings across all units, so we can't separate this business's roles. We'd rather show no number than one that isn't really this company's.
Source:
pfizer.wd1.myworkdayjobs.com
· Checked Nov 21, 2026
Financial Intelligence
"(h)
PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships."
"Item 2.02 Results of Operations and Financial Condition: On August 4, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein."
"Item 7.01 Regulation FD Disclosure: Following the disclosure of Pfizer’s Chief Financial Officer transition announcement on June 18, 2026, Pfizer today is reaffirming its fiscal year 2026 guidance introduced December 16, 2025 and reaffirmed on its first quarter earnings call on May 5, 2026. The company is reaffirming all components of its full-year 2026 guidance previously announced, including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a Range of $2.80 to $3.00. Ad"
"Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers: On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreement"
"(h)
PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships."
"Item 2.02 Results of Operations and Financial Condition: On May 5, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the first quarter of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein."
"For 2023, the total adjustments of $246 million included charges of (i) $474 million for certain legal matters, primarily representing certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition matters and (ii) $127 million mostly related to our equity-method accounting pro-rata share of intangible asset amortization and impairments, costs of separating from GSK and restructur"
"Divestitures
Divestiture of Early-Stage Rare Disease Gene Therapy Portfolio–
–On September 19, 2023, we completed an agreement with Alexion, under which Alexion purchased and licensed the assets of our early-stage rare disease gene therapy portfolio."
"2023 included, among other things, (i) dividend income of $
265
million from our investment in ViiV and $
211
million from our investment in Nimbus resulting from Takeda’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary and (ii) a $
222
million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion."
"(h)
PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships."
"(g)
PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships."
"(f)
PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships."
"For 2023, the total adjustments of $246 million included charges of (i) $474 million for certain legal matters, primarily representing certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition matters and (ii) $127 million mostly related to our equity-method accounting pro-rata share of intangible asset amortization and impairments, costs of separating from GSK and restructur"
"Divestitures
Divestiture of Early-Stage Rare Disease Gene Therapy Portfolio–
–On September 19, 2023, we completed an agreement with Alexion, under which Alexion purchased and licensed the assets of our early-stage rare disease gene therapy portfolio."
"and Subsidiary Companies
associated with PC1, related to finite-lived licensing agreements, and reflected updated contract manufacturing forecasts reflecting changes to market dynamics."
"The third quarter and first nine months of 2023 included, among other things, a $
222
million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion."
"(i)
PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships."
"For the third quarter of 2023, the total
Other (income)/deductions––net
adjustment of $85 million primarily included a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion, partially offset by charges of $71 million for certain legal matters, representing legal obligations related to pre-acquisition matters and certain product liability expenses related to products discontinued and/or divested by Pfizer."
"(g)
PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships."
"CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with DMD did not meet its primary endpoint of improvement in motor function among boys 4 to 7 years of age treated with the gene therapy compared to placebo."
"(g)
PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships."
Source: SEC EDGAR · Retrieved Nov 22, 2026
Frequently Asked Questions About Pfizer CentreOne
How many FDA inspections does Pfizer CentreOne have on record?
CDMO Signal tracks 4 FDA inspections for Pfizer CentreOne, sourced from the FDA inspection database. See the full inspection history above.
Has Pfizer CentreOne received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Pfizer CentreOne.
Does Pfizer CentreOne hold EMA or MHRA GMP certificates?
CDMO Signal tracks 15 EMA GMP certificates for Pfizer CentreOne.
How many clinical programs is Pfizer CentreOne linked to?
Pfizer CentreOne is associated with 369 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Pfizer CentreOne's CDMO Signal Score?
Pfizer CentreOne has a Signal Score of 90/100, based on quality, operations, financial stability, and capacity data.
Evaluating Pfizer CentreOne for a manufacturing program?
Use the free AI matchmaker to compare Pfizer CentreOne against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
AbbVie Contract Manufacturing
North Chicago, Illinois, United States
Small Molecule API, High-Potency APIs, Biologics, ADC / Bioconjugation, Sterile Fill-Finish, Lyophilization, Prefilled Syringes, Oral Solid Dose, Hot-Melt Extrusion, Oral Liquids, Topicals
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
Signal Score: 86.9
Biologics, ADC, Small Molecule API, High-Potency APIs, Oral Solid Dose
Lonza
Basel, Switzerland
Signal Score: 72.8
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
Shilpa Medicare
India (registered sites)
Small Molecule API, Oral Solid Dose, Sterile Fill-Finish, Biologics, Peptides & Oligos
NerPharMa
Nerviano (Milan), Italy
High-Potency APIs, Oncology Products, Small Molecule API, Sterile Injectables, Oral Solid Dose, Biologics
Compare Pfizer CentreOne with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.